



## News/Appointments

**Dr. Aristeia Galanopoulou** was elected as co-Editor-in-Chief of *Epilepsia Open*, the new open access journal of the International League Against Epilepsy. *Epilepsia Open* will publish high quality clinical, translational, and basic science research articles on epilepsy, including negative and failure to confirm studies.

**Dr. Elissa Yozawitz** was appointed to the International League Against Epilepsy Neonatal Seizure Guidelines Update Task Force. The aim of the task force is to develop evidence based guidelines for the diagnosis, treatment and management of neonatal seizures according to the clinical practice guidelines for epilepsy by the ILAE Epilepsy Guidelines Working Group.

## Welcome to our new Pediatric Neurology Chief Residents:

The division of pediatric neurology is thrilled to welcome Dr. Nicole Brescia and Dr. Bridget Leone to our department.

**Dr. Brescia** graduated from Wayne State University School of Medicine and completed her pediatric residency at CHAM.

**Dr. Leone** graduated from SUNY Downstate College of Medicine and completed her pediatric residency at Mt. Sinai Hospital.

Welcome Nicole and Bridget!



## First Annual Neurocutaneous Event

Over 50 patients, families, and physicians were brought together by the CHAM Neurocutaneous Center for a NY Yankees vs Detroit Tigers game. The Children's Tumor Foundation and the CHAM neurology department sponsored the event.

The Neurocutaneous Center provides comprehensive care for patients with neurocutaneous disorders and is lead by **Dr. Fatema Malbari**.



## Drug Trial News:

Our pediatric epilepsy team, lead by **Dr. Jules Beal** is enrolling patients into a study to investigate the efficacy and safety of *Cannabidiol*. It is a DOH compassionate use trial entitled A Phase 1 Observational Study of Cannabidiol as a Compassionate Use Treatment for Drug Resistant Epilepsies.

## Publications:

- Djukic A**, Holtzer R, **Shinnar S**, Muzumdar H, Rose SA, Mowrey W, **Galanopoulou AS**, **Shinnar R**, Jankowski JJ, Feldman JF, Pillai S, **Moshé SL**. Pharmacologic Treatment of Rett Syndrome With Glatiramer Acetate. *Pediatr Neurology*. In press
- Galanopoulou AS**, Wong M, Binder D, Hartman AL, Powell EM, Roopra A, Staba R, Vezzani A, Fureman B, Dingledine R; American Epilepsy Society (AES)/National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Benchmarks Stewards. 2014 Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression. *Epilepsy Curr*, 16(3): 187-91, 2016.
- Hesdorffer DC, **Shinnar S**, Lax DN, Pellock JM, Nordli DR Jr, Seinfeld S, Gallentine W, Frank LM, Lewis DV, **Shinnar RC**, Bello JA, Chan S, Epstein LG, **Moshé SL**, Liu B, Sun S; FEBSTAT study team. Risk factors for subsequent febrile seizures in the FEBSTAT study. *Epilepsia*. 57(7):1042-7, 2016.
- Janáčková S, Boyd S, **Yozawitz E**, Tsuchida T, Lamblin MD, Gueden S, Pressler R. Electroencephalographic characteristics of epileptic seizures in preterm neonates. *Clin Neurophysiol*. 4;127(8):2721-2727, 2016.
- Khrapunov S, Tao Y, Cheng H, Padlan CF, Harris R, **Galanopoulou AS**, Grealley JM, Girvin ME, Brenowitz MD. MeCP2 binding cooperativity inhibits DNA modification specific recognition. *Biochemistry* (2016) in press
- Malbari F**, Gershon TR, Garvin JH, Allen JC, Khakoo Y, Levy AS, Dunkel IJ. Psychiatric manifestations as initial presentation for pediatric CNS germ cell tumors, a case series. *Childs Nerv Syst*. 32(8), 1359-1362, 2016.
- Nariai H**, Price D, Jada A, et al. Prenatally diagnosed aggressive intracranial immature teratoma- clinicopathological correlation. *Fetal and Pediatr Pathol*. 35 (4): 260-4, 2016.
- Spiciarich, M.**, **Moshé, SL**. Voltage-Gated P/Q Type Calcium Channel Antibodies Associated With Cerebellar Degeneration. *Pediatric Neurology*. In press

## Tri-State Rett Syndrome Center News

The team of researchers at the Tri State Rett Syndrome Center, lead by **Dr. Aleksandra Djukic**, has conducted two, phase 2 treatment trials since 2014. Administration of Copaxone lead to significant improvement in several disease related symptoms and have been recently published. Results of recently closed trial with Lovastatin are being analyzed. Both Copaxone and Lovastatin have a potential of influencing "downstream targets" regulated by disease causing mutation on the MECP2 gene.

## LINCS program (Linking Individual Needs of Children with Services)

We have an expanded comprehensive care clinic that is a collaboration between **Dr. Susan Duberstein**, Dr. Kathryn Scharbach, and Dr. David Cancel which improves patients' access to care.